Product Images Divalproex Sodium
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 7 images provide visual information about the product associated with Divalproex Sodium NDC 70518-3459 by Remedyrepack Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
MM2 - Divalproex Sodium 250mg 70518 3459 01
This is a description of Divalproex Sodium delayed-release tablet, with a strength of 250 mg, supplied in a pack of 1. The tablets should be swallowed whole and not crushed or chewed. The medication is categorized as a Valproic Acid Activity Orepack HD2, and is available only with a prescription. The NDC number for this drug is 70518-3459-01, and the lot number and expiry date are not available in the given text. The manufacturer is Upsher-Smith Labs, Inc. of Minneapolis, MN, and the drug should be kept out of the reach of children. The package insert should be consulted for further instructions, and the drug should be stored at 20-25°C (88-77°F), with excursions permitted to 15-30°C (59-86°F) [according to USP]. The drug has been repackaged by RemedyRepack Inc. of Indiana, PA, and their contact number is 724.465.8762.*
Remedy_Label - Remedy Label
Divalproex Sodium is a delayed-release tablet used for Valproic Acid activity. Each box contains 100 tablets of 250 mg each. The tablets should not be crushed or chewed, and should be swallowed whole. It is being repackaged by RemedyRepack Inc. and should be stored at 20-25°C (88-77°F); excursions permitted o 15-30°C (59-86°F) [See USP]. The direction for usage can be found in the package insert. Keep this and all medication out of the reach of children. Lot number and expiration date information is provided.*
Chemical Structure - divalproex 01
Figure 1 - divalproex 02
The text seems to be a table or graph showing percentages and acronyms for studies. It is not possible to generate a useful description without more context.*
Figure 2 - divalproex 03
The text represents a chart or table comparing the reduction in CPS Rate for Divalproex sodium and Placebo. The chart shows percentages for improvement, no change, and worsening for both treatments. The percentages range from -50% to 100%.*
Figure 3 - divalproex 04
This document appears to be a graph showing the percentage reduction in CPS (Central Pain Syndrome) rate with high and low doses of treatment. There is also a visual representation of the percentage of patients experiencing improvement or worsening in their condition, as well as those experiencing no change.*
Figure 4 - divalproex 05
The text is not useful as it consists of only a few drug names and study references. It does not contain any contextual information or complete sentences to provide a description.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.